Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins
Top Cited Papers
- 28 October 2011
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 334 (6055), 498-501
- https://doi.org/10.1126/science.1207478
Abstract
Ultralow molecular weight (ULMW) heparins are sulfated glycans that are clinically used to treat thrombotic disorders. ULMW heparins range from 1500 to 3000 daltons, corresponding from 5 to 10 saccharide units. The commercial drug Arixtra (fondaparinux sodium) is a structurally homogeneous ULMW heparin pentasaccharide that is synthesized through a lengthy chemical process. Here, we report 10- and 12-step chemoenzymatic syntheses of two structurally homogeneous ULMW heparins (MW = 1778.5 and 1816.5) in 45 and 37% overall yield, respectively, starting from a simple disaccharide. These ULMW heparins display excellent in vitro anticoagulant activity and comparable pharmacokinetic properties to Arixtra, as demonstrated in a rabbit model. The chemoenzymatic approach is scalable and shows promise for a more efficient route to synthesize this important class of medicinal agent.Keywords
This publication has 34 references indexed in Scilit:
- Expression of heparan sulfate sulfotransferases in Kluyveromyces lactis and preparation of 3'-phosphoadenosine-5'-phosphosulfateGlycobiology, 2011
- First oral warfarin alternative approved in the USNature Reviews Drug Discovery, 2010
- Chemoenzymatic Design of Heparan Sulfate Oligosaccharides*Journal of Biological Chemistry, 2010
- E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursorBiotechnology & Bioengineering, 2010
- Lessons learned from the contamination of heparinNatural Product Reports, 2009
- Solution Structures of Chemoenzymatically Synthesized Heparin and Its PrecursorsJournal of the American Chemical Society, 2008
- Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical eventsNature Biotechnology, 2008
- Triggers, targets and treatments for thrombosisNature, 2008
- Engineering sulfotransferases to modify heparan sulfateNature Chemical Biology, 2008
- Anticoagulant heparan sulfate: structural specificity and biosynthesisApplied Microbiology and Biotechnology, 2007